--CV Sciences, Inc., a preeminent leader in hemp derived cannabidiol products, today announced the launch of ProCBD™, a full product line of clinical strength CBD products available exclusively ...

CV Sciences is trading at just a 4.2x EV/Sales multiple, which we think is low given that the company is profitable and growing revenues in excess of 30% on a YoY basis.

I can see why a risk-loving investor might take a gamble on CV Sciences (OTCMKTS: CVSI). Those who have already taken the plunge have done quite well. CV Sciences, somewhat incredibly, has risen ...

CV Sciences, Inc. (OTCQB: CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, ...

CV Sciences, Inc. (OTCQB: CVSI) a hemp-focused wellness company announced on Tuesday its financial results for the second quarter that ended June 30, 2024, revealing a flat revenue year-over-year ...

CV Sciences has spent the last 12 months in free fall. The company's Q3 2019 earnings results confirmed many fears selling shareholders would have had.

CV Sciences (PRNewsfoto/CV Sciences, Inc.) "We are thrilled that Extract Labs and its employees are joining CV Sciences as another milestone in our transition to a thriving health and wellness ...

CV Sciences, Inc. (OTCQB: CVSI) released its financial results today for the first quarter ended March 31, 2023, revealing revenues of $4.1 million for the first quarter of 2023 compared to $4.4 ...

Morningstar brands and products Company Portfolio ...

Operator: Greetings. And welcome to the CV Sciences, Inc. First Quarter 2023 Conference call. At this time, all participants are in a listen-only mode.

CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting ...